Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.
Spending time in the sun without protection increases the risk of melanoma, but the potentially deadly skin cancer can occur even on sites with minimal sun exposure, doctors warn.
Five-Year Survival Observed In Longest Follow-Up Of Advanced Melanoma Patients Treated With Opdivo-Yervoy Combination
Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.
The Food and Drug Administration approved Bristol-Myers Squibb’s Opdivo for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.
The European Commission approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
The U.S. Food and Drug Administration approved Array BioPharma Inc.’s oral combination treatment for use in patients with the deadliest form of skin cancer.
Nektar Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the new molecular entity NKTR-181, a mu-opioid agonist for pain relief. The company also inked a non-exclusive clinical collaboration deal with Syndax Pharmaceuticals to develop Nektar’s NKTR-214, a CD122-biased agonist in combination with entinostat, Syndax’s HDAC inhibitor in metastatic melanoma.
The U.S. Food and Drug Administration approved Novartis AG’s Tafinlar and Mekinist combination therapy to treat an aggressive type of thyroid cancer.